CGRP in the trigeminovascular system: A role for CGRP, adrenomedullin and amylin receptors?

British Journal of Pharmacology

Volumn 170, Issue 7, 2013, Pages 1293-1307

  Walker, C S ^a,b   Hay, D L ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Amylin; calcitonin gene related peptide; CGRP; G protein coupled receptor; GPCR; migraine; trigeminal ganglia; trigeminovascular system

Indexed keywords

ADENYLATE CYCLASE; ADRENOMEDULLIN; AMYLIN RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR LIKE RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CAPSAICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; POTASSIUM CHLORIDE; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; CALCITONIN RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS;

BRAIN ARTERY; BRAIN BLOOD VESSEL; BRAIN STEM; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; MENINGEAL ARTERY; NERVE CONDUCTION; NERVOUS SYSTEM; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRIGEMINAL NUCLEUS; TRIGEMINOVASCULAR SYSTEM; TRIGEMINUS GANGLION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INNERVATION; METABOLISM; MIGRAINE DISORDERS; PATHOPHYSIOLOGY; TRIGEMINAL NERVE; VASODILATATION;

ADRENOMEDULLIN; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; CEREBRAL ARTERIES; HUMANS; MIGRAINE DISORDERS; RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; RECEPTORS, CALCITONIN; RECEPTORS, ISLET AMYLOID POLYPEPTIDE; SIGNAL TRANSDUCTION; TRIGEMINAL GANGLION; TRIGEMINAL NERVE; TRIGEMINAL NUCLEI; TRIGEMINAL NUCLEUS, SPINAL; VASODILATION;

EID: 84887643807     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12129     Document Type: Review

References (137)

1. Aiyar N, Daines RA, Disa J, Chambers PA, Sauermelch CF, Quiniou M, et al. (2001). Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 296: 768-775.
2. Alexander SP, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Ambalavanar R, Dessem D, (2009). Emerging peripheral receptor targets for deep-tissue craniofacial pain therapies. J Dent Res 88: 201-211.
4. Anderson LE, Seybold VS, (2004). Calcitonin gene-related peptide regulates gene transcription in primary afferent neurons. J Neurochem 91: 1417-1429.
5. Arbab MA, Delgado T, Wiklund L, Svendgaard NA, (1988). Brain stem terminations of the trigeminal and upper spinal ganglia innervation of the cerebrovascular system: WGA-HRP transganglionic study. J Cereb Blood Flow Metab 8: 54-63.
6. Awawdeh L, Lundy FT, Shaw C, Lamey PJ, Linden GJ, Kennedy JG, (2002). Quantitative analysis of substance P, neurokinin A and calcitonin gene-related peptide in pulp tissue from painful and healthy human teeth. Int Endod J 35: 30-36.
7. Bailey RJ, Hay DL, (2006). Pharmacology of the human CGRP1 receptor in Cos 7 cells. Peptides 27: 1367-1375.
8. Becskei C, Riediger T, Zund D, Wookey P, Lutz TA, (2004). Immunohistochemical mapping of calcitonin receptors in the adult rat brain. Brain Res 1030: 221-233.
9. Bower RL, Valdvogel HJ, Faull RLM, Hay DL, (2011). Calcitonin Receptor and receptor activity-modifying protein 1 expression in the human medulla. British Pharmacological Society Winter Meeting. London 2011. Available at: http://www.pa2online.org/abstracts/vol9issue3abst066p.pdf (accessed 3/11/2013).
10. Brain SD, Grant AD, (2004). Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84: 903-934.
11. Buhlmann N, Leuthauser K, Muff R, Fischer JA, Born W, (1999). A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 140: 2883-2890.
12. Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A, (2006). Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 99: 1338-1350.
13. Cady RJ, Glenn JR, Smith KM, Durham PL, (2011). Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization. Mol Pain 7: 94.
14. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL, (2009). Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 49: 1258-1266.
15. Capuano A, Curro D, Dello Russo C, Tringali G, Pozzoli G, Di Trapani G, et al. (2007). Nociceptin (1-13)NH2 inhibits stimulated calcitonin-gene-related- peptide release from primary cultures of rat trigeminal ganglia neurones. Cephalalgia 27: 868-876.
16. Casey ML, Smith J, Alsabrook G, MacDonald PC, (1997). Activation of adenylyl cyclase in human myometrial smooth muscle cells by neuropeptides. J Clin Endocrinol Metab 82: 3087-3092.
17. Ceruti S, Villa G, Fumagalli M, Colombo L, Magni G, Zanardelli M, et al. (2011). Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain. J Neurosci 31: 3638-3649.
18. Champion HC, Bivalacqua TJ, Pierce RL, Murphy WA, Coy DH, Hyman AL, et al. (2003). Responses to human CGRP, ADM, and PAMP in human thymic arteries. Am J Physiol Regul Integr Comp Physiol 284: R531-R537.
19. Choksi T, Hay DL, Legon S, Poyner DR, Hagner S, Bloom SR, et al. (2002). Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br J Pharmacol 136: 784-792.
20. Cox HM, Tough IR, (1994). Calcitonin gene-related peptide receptors in human gastrointestinal epithelia. Br J Pharmacol 113: 1243-1248.
21. Cuello AC, Del Fiacco M, Paxinos G, (1978). The central and peripheral ends of the substance P-containing sensory neurones in the rat trigeminal system. Brain Res 152: 499-500.
22. De Corato A, Lisi L, Capuano A, Tringali G, Tramutola A, Navarra P, et al. (2011). Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1beta pro-inflammatory effects. J Neuroimmunol 237: 39-46.
23. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, et al. (2008). Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)- N-(3-(7-methyl-1H-indazol-5 -yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl) propan-2-yl)piperidine-1-carboxami de (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 51: 4858-4861.
24. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J, (2011). BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31: 573-584.
25. Disa J, Parameswaran N, Nambi P, Aiyar N, (2000). Involvement of cAMP-dependent protein kinase and pertussis toxin-sensitive G-proteins in CGRP mediated JNK activation in human neuroblastoma cell line. Neuropeptides 34: 229-233.
26. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, et al. (2000). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420-423.
27. Edvinsson L, Uddman R, (2005). Neurobiology in primary headaches. Brain Res Brain Res Rev 48: 438-456.
28. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C, (1985). Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 58: 213-217.
29. Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R, (1987a). Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7: 720-728.
30. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R, (1987b). Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 21: 431-437.
31. Edvinsson L, Goadsby PJ, Uddman R, (2001). Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal 1: 168-180.
32. Edvinsson L, Nilsson E, Jansen-Olesen I, (2007). Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150: 633-640.
33. Edvinsson L, Chan KY, Eftekhari S, Vries R, Saveland H, et al. (2010). Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 30: 1233-1240.
34. Eftekhari S, Edvinsson L, (2010). Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 3: 369-378.
35. Eftekhari S, Edvinsson L, (2011). Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 12: 112.
36. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L, (2010). Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169: 683-696.
37. Fernandez AP, Serrano J, Martinez-Murillo R, Martinez A, (2010). Lack of adrenomedullin in the central nervous system results in apparently paradoxical alterations on pain sensitivity. Endocrinology 151: 4908-4915.
38. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB, (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups and fingerprints. Mol Pharmacol 63: 1256-1272.
39. Gebre-Medhin S, Mulder H, Zhang Y, Sundler F, Betsholtz C, (1998). Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice. Brain Res Mol Brain Res 63: 180-183.
40. Goadsby PJ, (2002). Migraine management: contrasting patient preferences with current clinical end points: introduction. Headache 42 (Suppl. 1): 1-2.
41. Goadsby PJ, Edvinsson L, Ekman R, (1988). Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23: 193-196.
42. Goadsby PJ, Edvinsson L, Ekman R, (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183-187.
43. Gupta S, Mehrotra S, Villalon CM, Garrelds IM, de, Vries R, van, Kats JP, et al. (2006). Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 530: 107-116.
44. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, et al. (2010). Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 18: 1083-1093.
45. Hagner S, Welz H, Kicic A, Alrifai M, Marsh LM, Sutanto EN, et al. (2012). Suppression of adrenomedullin contributes to vascular leakage and altered epithelial repair during asthma. Allergy 67: 998-1006.
46. Hansen JM, Hauge AW, Olesen J, Ashina M, (2010). Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30: 1179-1186.
47. Hasbak P, Sams A, Schifter S, Longmore J, Edvinsson L, (2001). CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist. Br J Pharmacol 133: 1405-1413.
48. Hasbak P, Saetrum Opgaard O, Eskesen K, Schifter S, Arendrup H, Longmore J, et al. (2003). Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304: 326-333.
49. Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR, (2002). A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol 137: 80-86.
50. Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, Poyner DR, (2003). CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. Br J Pharmacol 140: 477-486.
51. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM, (2005). Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 67: 1655-1665.
52. Hay DL, Christopoulos G, Christopoulos A, Sexton PM, (2006). Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl] carbonyl]pentyl]amino]-1- [(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4- (1,4-dihydro-2-oxo-3(2 H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 70: 1984-1991.
53. Hay DL, Walker CS, Poyner DR, (2011). Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges. Endocr Relat Cancer 18: C1-C14.
54. Helke CJ, Jacobowitz DM, Thoa NB, (1981). Capsaicin and potassium evoked substance P release from the nucleus tractus solitarius and spinal trigeminal nucleus in vitro. Life Sci 29: 1779-1785.
55. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, et al. (2011). Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31: 712-722.
56. Hilairet S, Belanger C, Bertrand J, Laperriere A, Foord SM, Bouvier M, (2001). Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem 276: 42182-42190.
57. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. (2008). Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372: 2115-2123.
58. Hoffmann J, Wecker S, Neeb L, Dirnagl U, Reuter U, (2012). Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. Cephalalgia 32: 659-667.
59. Hong KW, Yoo SE, Yu SS, Lee JY, Rhim BY, (1996). Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am J Physiol 270 (1 Pt 2): H317-H323.
60. Huang L, Li B, Li W, Guo H, Zou F, (2009). ATP-sensitive potassium channels control glioma cells proliferation by regulating ERK activity. Carcinogenesis 30: 737-744.
61. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, et al. (2008). The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 118: 29-39.
62. Ishihara T, Kato J, Kitamura K, Katoh F, Fujimoto S, Kangawa K, et al. (1997). Production of adrenomedullin in human vascular endothelial cells. Life Sci 60: 1763-1769.
63. Ishizaka Y, Tanaka M, Kitamura K, Kangawa K, Minamino N, Matsuo H, et al. (1994). Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. Biochem Biophys Res Commun 200: 642-646.
64. Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y, (1998). Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology 139: 3432-3441.
65. Jansen-Olesen I, Kaarill L, Edvinsson L, (2001). Characterization of CGRP(1) receptors in the guinea pig basilar artery. Eur J Pharmacol 414: 249-258.
66. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L, (2003). In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481: 207-216.
67. Kitazono T, Heistad DD, Faraci FM, (1993). Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol 265 (2 Pt 2): H581-H585.
68. Koulchitsky S, Fischer MJ, Messlinger K, (2009). Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 29: 408-417.
69. Kubota M, Moseley JM, Butera L, Dusting GJ, MacDonald PS, Martin TJ, (1985). Calcitonin gene-related peptide stimulates cyclic AMP formation in rat aortic smooth muscle cells. Biochem Biophys Res Commun 132: 88-94.
70. Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, et al. (2008). Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507: 1277-1299.
71. Li J, Vause CV, Durham PL, (2008). Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196: 22-32.
72. Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, et al. (2012). Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H- cyclohepta[b]pyri din-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): an oral Calcitonin Gene-Related Peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem 55: 10644-10651.
73. Ma W, Chabot JG, Quirion R, (2006). A role for adrenomedullin as a pain-related peptide in the rat. Proc Natl Acad Sci U S A 103: 16027-16032.
74. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333-339.
75. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, et al. (2002). Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277: 14294-14298.
76. Mangmool S, Shukla AK, Rockman HA, (2010). beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol 189: 573-587.
77. Marshal I, Wisskirchen FM, (2000). CGRP receptor heterogeneity; use of CGRP8-37. In:, Poyner D, Dickerson I, Brain SD, (eds). The CGRP Family. Landes Bioscience: Texax, pp. 13-23.
78. Meens MJ, Mattheij NJ, van, Loenen PB, Spijkers LJ, Lemkens P, Nelissen J, et al. (2012). G-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide. Br J Pharmacol 166: 297-308.
79. Messlinger K, Fischer MJ, Lennerz JK, (2011). Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med 60: 82-89.
80. Miller PS, Barwell J, Poyner DR, Wigglesworth MJ, Garland SL, Donnelly D, (2010). Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem Biophys Res Commun 391: 437-442.
81. Moore EL, Salvatore CA, (2012). Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol 166: 66-78.
82. Moreno MJ, Cohen Z, Stanimirovic DB, Hamel E, (1999). Functional calcitonin gene-related peptide type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, and cerebromicrovascular or astroglial cells in culture. J Cereb Blood Flow Metab 19: 1270-1278.
83. Mori Y, Takayasu M, Suzuki Y, Shibuya M, Yoshida J, Hidaka H, (1997). Effects of adrenomedullin on rat cerebral arterioles. Eur J Pharmacol 330: 195-198.
84. Mulder H, Ahren B, Sundler F, (1997). Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats. J Endocrinol 152: 495-501.
85. Nakamoto H, Soeda Y, Takami S, Minami M, Satoh M, (2000). Localization of calcitonin receptor mRNA in the mouse brain: coexistence with serotonin transporter mRNA. Brain Res Mol Brain Res 76: 93-102.
86. Ng KY, Yeung BH, Wong YH, Wise H, (2012). Isolated dorsal root ganglion neurones inhibit receptor-dependent adenylyl cyclase activity in associated glial cells. Br J Pharmacol 168: 746-760.
87. Nishio K, Akai Y, Murao Y, Doi N, Ueda S, Tabuse H, et al. (1997). Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 25: 953-957.
88. Olesen J, Ashina M, (2011). Emerging migraine treatments and drug targets. Trends Pharmacol Sci 32: 352-359.
89. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350: 1104-1110.
90. Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG, (2002). Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22: 620-629.
91. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW, (2005). Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys 61: 1523-1534.
92. Paxinos G, Chai SY, Christopoulos G, Huang XF, Toga AW, Wang HQ, et al. (2004). In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain. J Chem Neuroanat 27: 217-236.
93. Petersen KA, Nilsson E, Olesen J, Edvinsson L, (2005). Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 25: 424-432.
94. Poyner DR, Soomets U, Howitt SG, Langel U, (1998). Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides. Br J Pharmacol 124: 1659-1666.
95. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54: 233-246.
96. Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL, (2012). Receptor activity-modifying protein dependent impairment of calcitonin receptor splice variant Delta(1-47)hCT((a)) function. Br J Pharmacol 168: 644-657.
97. Raddant AC, Russo AF, (2011). Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 13: e36.
98. Rapoport AM, (2010). New acute treatments for headache. Neurol Sci 31 (Suppl. 1): S129-S132.
99. van Rossum D, Hanisch UK, Quirion R, (1997). Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21: 649-678.
100. Sacerdote P, Levrini L, (2012). Peripheral mechanisms of dental pain: the role of substance P. Mediators Inflamm doi: 10.155/2012/951920.
101. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, et al. (2008). Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3- difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324: 416-421.
102. Salvatore CA, Moore EL, Calamari A, Cook JJ, Michener MS, O'Malley S, et al. (2010). Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther 333: 152-160.
103. Sams A, Jansen-Olesen I, (1998). Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries. Neurosci Lett 258: 41-44.
104. Serrano J, Uttenthal LO, Martinez A, Fernandez AP, Martinez de Velasco J, Alonso D, et al. (2000). Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy. Brain Res 853: 245-268.
105. Sheykhzade M, Nyborg NC, (1998). Characterization of calcitonin gene-related peptide (CGRP) receptors in intramural coronary arteries from male and female Sprague Dawley rats. Br J Pharmacol 123: 1464-1470.
106. Sibilia V, Pagani F, Lattuada N, Rapetti D, Guidobono F, Netti C, (2000). Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. Brain Res 854: 79-84.
107. Silberstein SD, (2004). Migraine pathophysiology and its clinical implications. Cephalalgia 24 (Suppl. 2): 2-7.
108. Simonetti M, Giniatullin R, Fabbretti E, (2008). Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem 283: 18743-18752.
109. Sixt ML, Messlinger K, Fischer MJ, (2009). Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 132 (Pt 11): 3134-3141.
110. Smith D, Hill RG, Edvinsson L, Longmore J, (2002). An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22: 424-431.
111. Sone M, Takahashi K, Satoh F, Murakami O, Totsune K, Ohneda M, et al. (1997). Specific adrenomedullin binding sites in the human brain. Peptides 18: 1125-1129.
112. South EH, Ritter RC, (1986). Substance P-containing trigeminal sensory neurons project to the nucleus of the solitary tract. Brain Res 372: 283-289.
113. Stachniak TJ, Krukoff TL, (2003). Receptor activity modifying protein 2 distribution in the rat central nervous system and regulation by changes in blood pressure. J Neuroendocrinol 15: 840-850.
114. Stangl D, Muff R, Schmolck C, Fischer JA, (1993). Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation: identification of receptor subtypes. Endocrinology 132: 744-750.
115. Stankewitz A, May A, (2011). Increased limbic and brainstem activity during migraine attacks following olfactory stimulation. Neurology 77: 476-482.
116. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. (2007). The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27: 193-210.
117. Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, et al. (1994). Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201: 1160-1166.
118. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L, (1999). Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76: 176-183.
119. Tajti J, Kuris A, Vecsei L, Xu CB, Edvinsson L, (2011). Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2. Cephalalgia 31: 95-105.
120. Tfelt-Hansen P, (2011). Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 51: 118-123.
121. Tfelt-Hansen P, (2012). Clinical pharmacology of current and future drugs for the acute treatment of migraine: a review and an update. Curr Clin Pharmacol 7: 66-72.
122. Tfelt-Hansen P, Olesen J, (2011). Possible site of action of CGRP antagonists in migraine. Cephalalgia 31: 748-750.
123. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A, (2005). The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 49: 65-76.
124. Tobin AB, Butcher AJ, Kong KC, (2008). Location, location, location. site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 29: 413-420.
125. Tolcos M, Harding R, Loeliger M, Breen S, Cock M, Duncan J, et al. (2003). The fetal brainstem is relatively spared from injury following intrauterine hypoxemia. Brain Res Dev Brain Res 143: 73-81.
126. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J, (2005). No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58: 561-568.
127. Udawela M, Christopoulos G, Morfis M, Tilakaratne N, Christopoulos A, Sexton PM, (2008). The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors. Regul Pept 145: 65-71.
128. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J, (1985). Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62: 131-136.
129. Vause CV, Durham PL, (2009). CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 110: 811-821.
130. Wacnik PW, Baker CM, Herron MJ, Kren BT, Blazar BR, Wilcox GL, et al. (2005). Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 115: 95-106.
131. Walker CS, Hay DL, (2011). Pharmacological characterisation of calcitonin gene-related peptide receptors in primary cultured rat trigeminal ganglia derived neurons. British Pharmacological Society Winter Meeting. London 2011. Available at: http://www.pa2online.org/abstracts/vol9issue3abst067p.pdf (accessed 3/11/2013).
132. Walker CS, Conner AC, Poyner DR, Hay DL, (2010). Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 31: 476-483.
133. Wellman GC, Quayle JM, Standen NB, (1998). ATP-sensitive K+ channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol 507 (Pt 1): 117-129.
134. Wisskirchen FM, Gray DW, Marshall I, (1999). Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by h(alpha) CGRP(8-37). Br J Pharmacol 128: 283-292.
135. Wookey PJ, McLean CA, Hwang P, Furness SG, Nguyen S, Kourakis A, et al. (2012). The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172. Histopathology 60: 895-910.
136. Yoshimoto R, Mitsui-Saito M, Ozaki H, Karaki H, (1998). Effects of adrenomedullin and calcitonin gene-related peptide on contractions of the rat aorta and porcine coronary artery. Br J Pharmacol 123: 1645-1654.
137. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF, (2007). Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27: 2693-2703.